Matches in SemOpenAlex for { <https://semopenalex.org/work/W4244149177> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W4244149177 endingPage "S64" @default.
- W4244149177 startingPage "S64" @default.
- W4244149177 abstract "The Ca2+ release activated Ca2+ (CRAC) channel is an exciting new pharmacological target for the treatment of Inflammatory Bowel Disease (IBD) because it is upstream in the inflammatory cascade and absolutely necessary for immune responses. Calcium-selective CRAC channels become activated when T cells recognize antigen and allow calcium influx to the cytoplasm leading to increased NF-κB and NFAT-mediated gene expression driving inflammation. We have developed VV2003 which is a small molecule that blocks the CRAC channel and can be delivered orally. It has limited epithelial permeability allowing VV2003 to function locally at the site of inflammation with little risk for systemic complications. Following oral administration in healthy and colitic mice, VV2003 demonstrates low systemic absorption while maintaining therapeutic levels in the colon tissue for greater than 12 hours. In rat pharmacokinetic studies, VV2003 demonstrates low percent bioavailability and rapid clearance. The drug candidate diffuses into the intestinal mucosa and submucosa where it ameliorates inflammation without systemic activity. We have tested VV2003 in the DSS and Adoptive Transfer mouse models for colitis and have seen improvements in multiple endpoints including: disease activity index, fecal calprotectin and histologic scores. Notably, it is non-inferior to several systemically-active treatments which are currently the standard of care. We find that the CRAC channel is upregulated in biopsy samples from patients with IBD, and VV2003 suppresses inflammatory cytokines from PBMCs in-vitro. Importantly, there have been no signs of toxicity in any of our experiments. Overall, these data demonstrate that VV2003 has potential to become a novel next-generation oral therapy for colitis because it effectively limits leukocyte function in-vitro and in-vivo and is expected to have local delivery to the sites of pathology with minimal off target effects. In the near future, we plan to begin clinical trials to determine if VV2003 will be effective in treating patients with IBD. This project is supported by: VA CDA 5IK2BX003518, NIH NCATS TR001415; NIH NIAID R43AI134205." @default.
- W4244149177 created "2022-05-12" @default.
- W4244149177 creator A5033073935 @default.
- W4244149177 creator A5039622853 @default.
- W4244149177 creator A5052028347 @default.
- W4244149177 creator A5056296835 @default.
- W4244149177 creator A5063194488 @default.
- W4244149177 creator A5064381663 @default.
- W4244149177 creator A5067934290 @default.
- W4244149177 creator A5071998711 @default.
- W4244149177 creator A5086674168 @default.
- W4244149177 creator A5091903628 @default.
- W4244149177 date "2019-02-01" @default.
- W4244149177 modified "2023-10-18" @default.
- W4244149177 title "P137 LOCAL CRAC CHANNEL BLOCKADE TREATS COLITIS IN MICE" @default.
- W4244149177 doi "https://doi.org/10.1093/ibd/izy393.153" @default.
- W4244149177 hasPublicationYear "2019" @default.
- W4244149177 type Work @default.
- W4244149177 citedByCount "0" @default.
- W4244149177 crossrefType "journal-article" @default.
- W4244149177 hasAuthorship W4244149177A5033073935 @default.
- W4244149177 hasAuthorship W4244149177A5039622853 @default.
- W4244149177 hasAuthorship W4244149177A5052028347 @default.
- W4244149177 hasAuthorship W4244149177A5056296835 @default.
- W4244149177 hasAuthorship W4244149177A5063194488 @default.
- W4244149177 hasAuthorship W4244149177A5064381663 @default.
- W4244149177 hasAuthorship W4244149177A5067934290 @default.
- W4244149177 hasAuthorship W4244149177A5071998711 @default.
- W4244149177 hasAuthorship W4244149177A5086674168 @default.
- W4244149177 hasAuthorship W4244149177A5091903628 @default.
- W4244149177 hasConcept C126322002 @default.
- W4244149177 hasConcept C128057223 @default.
- W4244149177 hasConcept C155520015 @default.
- W4244149177 hasConcept C189938988 @default.
- W4244149177 hasConcept C203014093 @default.
- W4244149177 hasConcept C2775862500 @default.
- W4244149177 hasConcept C2776090121 @default.
- W4244149177 hasConcept C2776252253 @default.
- W4244149177 hasConcept C2776914184 @default.
- W4244149177 hasConcept C2778260677 @default.
- W4244149177 hasConcept C2779134260 @default.
- W4244149177 hasConcept C2779727006 @default.
- W4244149177 hasConcept C2911091166 @default.
- W4244149177 hasConcept C3019368612 @default.
- W4244149177 hasConcept C519063684 @default.
- W4244149177 hasConcept C71924100 @default.
- W4244149177 hasConcept C85520022 @default.
- W4244149177 hasConcept C87975464 @default.
- W4244149177 hasConcept C8891405 @default.
- W4244149177 hasConcept C90375314 @default.
- W4244149177 hasConcept C98274493 @default.
- W4244149177 hasConceptScore W4244149177C126322002 @default.
- W4244149177 hasConceptScore W4244149177C128057223 @default.
- W4244149177 hasConceptScore W4244149177C155520015 @default.
- W4244149177 hasConceptScore W4244149177C189938988 @default.
- W4244149177 hasConceptScore W4244149177C203014093 @default.
- W4244149177 hasConceptScore W4244149177C2775862500 @default.
- W4244149177 hasConceptScore W4244149177C2776090121 @default.
- W4244149177 hasConceptScore W4244149177C2776252253 @default.
- W4244149177 hasConceptScore W4244149177C2776914184 @default.
- W4244149177 hasConceptScore W4244149177C2778260677 @default.
- W4244149177 hasConceptScore W4244149177C2779134260 @default.
- W4244149177 hasConceptScore W4244149177C2779727006 @default.
- W4244149177 hasConceptScore W4244149177C2911091166 @default.
- W4244149177 hasConceptScore W4244149177C3019368612 @default.
- W4244149177 hasConceptScore W4244149177C519063684 @default.
- W4244149177 hasConceptScore W4244149177C71924100 @default.
- W4244149177 hasConceptScore W4244149177C85520022 @default.
- W4244149177 hasConceptScore W4244149177C87975464 @default.
- W4244149177 hasConceptScore W4244149177C8891405 @default.
- W4244149177 hasConceptScore W4244149177C90375314 @default.
- W4244149177 hasConceptScore W4244149177C98274493 @default.
- W4244149177 hasIssue "Supplement_1" @default.
- W4244149177 hasLocation W42441491771 @default.
- W4244149177 hasOpenAccess W4244149177 @default.
- W4244149177 hasPrimaryLocation W42441491771 @default.
- W4244149177 hasRelatedWork W1861349929 @default.
- W4244149177 hasRelatedWork W1974156051 @default.
- W4244149177 hasRelatedWork W1997714882 @default.
- W4244149177 hasRelatedWork W2065570876 @default.
- W4244149177 hasRelatedWork W2083741917 @default.
- W4244149177 hasRelatedWork W2258385876 @default.
- W4244149177 hasRelatedWork W2560068629 @default.
- W4244149177 hasRelatedWork W3088567775 @default.
- W4244149177 hasRelatedWork W4233212299 @default.
- W4244149177 hasRelatedWork W4244149177 @default.
- W4244149177 hasVolume "25" @default.
- W4244149177 isParatext "false" @default.
- W4244149177 isRetracted "false" @default.
- W4244149177 workType "article" @default.